News Releases
- July 1, 2021Annovis Bio CEO Wins 2021 PACT Enterprise Award for Life Sciences and Healthcare CEO
- June 24, 2021Annovis Bio CEO Selected as a Finalist in the 2021 PACT Enterprise Awards
- June 8, 2021Annovis Bio Expands Potential Application of ANVS401 to Infectious Diseases with New Preclinical Study
- June 3, 2021Annovis Bio to Present at Jefferies Virtual Healthcare Conference 2021
- June 1, 2021Annovis Bio’s ANVS401 Improves Speed and Accuracy in Alzheimer’s and in Parkinson’s Patients
- May 28, 2021Annovis Bio Engages Global Executive Search Leader Spencer Stuart to Expand its Board and Management Team
- May 27, 2021Annovis Bio, Inc. Announces Closing of $50 Million Public Offering
- May 23, 2021Annovis Bio, Inc. Announces Pricing of Public Offering
- May 21, 2021Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock
- May 21, 2021Annovis Bio Announces Positive Phase 2 Data – ANVS401 Improves Cognition in Alzheimer’s Disease - Patients’ Cognition Improved 3.3 Points on ADAS-Cog11
- ,
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - February 2024
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top